A5053546219- Blood properties and coagulation
- Blood Coagulation and Thrombosis Mechanisms
- Hemophilia Treatment and Research
- Erythropoietin and Anemia Treatment
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Adipokines, Inflammation, and Metabolic Diseases
- Cancer-related gene regulation
- Pluripotent Stem Cells Research
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Caveolin-1 and cellular processes
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Wnt/β-catenin signaling in development and cancer
- Diagnosis and Treatment of Venous Diseases
Sanofi (United States)
2020-2022
University of North Carolina at Chapel Hill
2017-2021
University of Colorado Denver
2014
Lung cancer is the leading cause of cancer-related deaths worldwide, and lung squamous carcinomas (LUSC) represent about 30% cases. Molecular aberrations in adenocarcinomas have allowed for effective targeted treatments, but corresponding therapeutic advances LUSC not materialized. However, immune checkpoint inhibitors sub-populations patients led to exciting responses. Using computational analyses The Cancer Genome Atlas, we identified a subset tumors characterized by dense infiltration...
Glycogen synthase kinase-3 (Gsk-3) activity is an important regulator of numerous signal transduction pathways. Gsk-3 the sum two largely redundant proteins, Gsk-3α and Gsk-3β, in general, a negative cellular signaling. Genetic deletion both Gsk-3β mouse embryonic stem cells (ESCs) has previously been shown to lead constitutive activation Wnt/β-catenin signaling pathway. However, addition Wnt signaling, all Gsk-3-regulated pathways, such as insulin are also affected simultaneously Gsk-3α-/-;...
The compositions of venous (red blood cell-rich) and arterial (platelet-rich) thrombi are mediated by distinct pathophysiologic processes; however, fibrin is a major structural component both. transglutaminase factor XIII (FXIII) stabilizes against mechanical biochemical disruption promotes red cell retention in contracted thrombi. Previous studies have shown inhibition decreases whole clot mass therefore, may be therapeutic target for reducing thrombosis. role FXIII thrombogenesis less...